Barcelona

• Clinical trial to assess the efficacy and safety of a vaccine for dust mite allergy Ended
  2024-514090-21-00 5 2020-08-05 Aetiological treatment of moderate - severe intermittent or persistent
• An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approv … Ended
  2023-507493-41-00 5 2020-08-04 relapsing multiple sclerosis (RMS)
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants with Melanoma (KEYMAK … Ended
  2023-506313-21-00 9 2020-08-03 PD-1 refractory melanoma
• Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult P … Ended
  2023-505125-14-00 4 2020-07-24 Acute Traumatic Cervical Spinal Cord Injury
• Open Label 2-Arm Study of Venetoclax in Combination with Azacitidine Versus Best Supportive Care after Allogeneic Stem Cell Transplantation … Ended
  2023-507222-17-00 5 2020-07-24 Acute Myeloid Leukaemia
• Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended
  2022-500820-31-00 4 2020-07-16 Recurrent or metastatic squamous cell carcinoma of the head and neck
• Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGROLT) Ended
  2023-509801-59-00 5 2020-07-09 Alopecia areata
• “Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Pat … Ended
  2024-514206-31-00 9 2020-07-09 Small cell lung cancer (SCLC).
• Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery Ended
  2024-511171-15-00 3 2020-07-06 Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who ha
• Clinical Trial to evaluate the efficacy of immunotherapy in a subset of Hormonal Receptor-positive/HER2-negative advanced breast cancer pati … Ended
  2023-508546-17-00 4 2020-07-01 Pre and post-menopausal women with locally advanced or metastatic HR+/
• A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) Ended
  2023-506873-36-00 5 2020-06-29 Frontotemporal dementia (FTD)
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended
  2023-505035-12-00 5 2020-06-12 RET fusion−positive, metastatic Non-Small Cell Lung Cancer
• A Long-term Safety Study of a Second Treatment with Darvadstrocel for Treating Complex Perianal Fistulas in Adults with Crohn's Disease Ended
  2022-503014-23-00 6 2020-06-03 Perianal fistulising Crohn´s disease
• Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission … Ended
  2023-507221-42-00 5 2020-06-03 Acute Myeloid Leukemia in First Remission
• A Study of Tiragolumab, an Anti-TIGIT Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab (an … Ended
  2022-502482-17-00 5 2020-05-19 Non-small cell lung cancer (NSCLC)
• A Phase 3 Study of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in AdultsUndergoin … Ended
  2024-514471-18-00 5 2020-05-13 Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Mar
• Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended
  2022-501972-25-00 5 2020-04-06 Locally Advanced Cervical Cancer
• Clinical research study to investigate efficacy and safety of Liposomal Cyclosporine A (L-CsA) in patients with Bronchiolitis Obliterans Syn … Ended
  2024-512448-41-00 5 2020-04-01 Bronchiolitis Obliterans Syndrome in Patients post Single or post Doub
• A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosi … Ended
  2023-507276-53-00 4 2020-03-23 Myelofibrosis
• A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination with Atezolizumab in Participants with Advanced and/ … Ended
  2023-503749-76-00 1 2020-03-06 Solid Tumors
• A Study to evaluate the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously … Ended
  2023-507389-15-00 4 2020-02-26 Advanced Melanoma
• A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM) Ended
  2023-508293-28-00 5 2020-02-20 Dermatomyositis
• Inhibition of AKT in combination with antibodies targeting the protein HER2 in patients with advanced or metastatic breast cancer and with a … Ended
  2023-508826-92-00 3 2020-02-14 Patients with PIK3CA-mutant, HER2-positive locally advanced or metasta
• A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents Ended
  2023-507904-30-00 3 2020-01-27 solid tumors

Showing 3,217–3,240 of 3,391 trials